drugset
Drugs / ANX007
last change Aug 2026 re-read 3 minutes ago

ANX007

also known as Vonaprument
Developed for
diffuse secondary choroid atrophy · open-angle glaucoma
Investigated by
Annexon, Inc.

Trials 4

today NCT06510816 · Ph 3 NCT04656561 · Ph 2 NCT04188015 · Ph 1 NCT03488550 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04188015 Jul 2018 → Jun 2019 open-angle glaucoma Annexon, Inc. Completed No outcome recorded
Phase 1 NCT03488550 Mar → Aug 2018 open-angle glaucoma Annexon, Inc. Completed No outcome recorded
Phase 21 trial · 1 met primary
Phase 2 NCT04656561 Feb 2021 → Mar 2023 diffuse secondary choroid atrophy Annexon, Inc. Completed Met primary
Phase 31 trial
Phase 3 NCT06510816 Jul 2024 → Oct 2026 expected diffuse secondary choroid atrophy Annexon, Inc. Active not recruiting No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2026-08-12 Annexon, Inc. Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study annexonbio.com ↗
2026-02-17 Annexon, Inc. Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy annexonbio.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ANX007 “Vonaprument (Formerly ANX007)” NCT06510816 ↗
3

NCT04188015 ↗

NCT04656561 ↗

NCT03488550 ↗
Known as Vonaprument ClinicalTrials.gov intervention name — accepted as the source's own label NCT06510816 ↗
Route Intravitreal “single intravitreal (IVT) injection” NCT03488550 ↗